Prosecution Insights
Last updated: April 19, 2026

Mirati Therapeutics Inc.

7 pending office actions

Portfolio Summary

7
Total Pending OAs
3
Final Rejections
4
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18286961 KRAS G12C INHIBITORS SEITZ, ANTHONY JOSEPH 1629 Non-Final OA Oct 13, 2023
18229662 QUINAZOLINE PAN-KRas INHIBITORS TOWNSLEY, SARA ELIZABETH 1629 Non-Final OA Aug 02, 2023
18274441 COMBINATION THERAPIES NOTTINGHAM, KYLE GREGORY 1621 Non-Final OA Jul 26, 2023
18032492 METHODS FOR TREATMENT OF LUNG CANCERS JOHANNSEN, DIANA B 1682 Final Rejection Apr 18, 2023
18026799 COMBINATION THERAPIES XIAO, YAN 1642 Non-Final OA Mar 16, 2023
18018422 SOS1 INHIBITORS DAVIS, BRIAN J 1614 Final Rejection Jan 27, 2023
17801733 SOS1 INHIBITORS VALLE, ERNESTO 1623 Final Rejection Aug 23, 2022

Managing Mirati Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month